2CURB-65 Score Interpretation Table
| Score | Group | 30-Day Mortality | Recommended Action |
|---|---|---|---|
| 0 | Group 1 | 0.7% | Home treatment likely appropriate |
| 1 | Group 1 | 2.1% | Home treatment; reassess if no improvement in 48h |
| 2 | Group 2 | 6.6% | Consider hospitalization or supervised outpatient care |
| 3 | Group 3 | 17.0% | Urgent inpatient admission; treat as severe CAP |
| 4–5 | Group 3 | ≈40% | Emergency admission; consider ICU assessment |
3CURB-65 in the Indian Clinical Context
Community-acquired pneumonia (CAP) is among the leading causes of hospitalisation and mortality in India. The disease burden is compounded by several factors unique to the Indian setting — high prevalence of Klebsiella pneumoniae (a gram-negative organism not covered by standard beta-lactam monotherapy), drug-resistant Streptococcus pneumoniae, rising rates of TB-associated lung disease, and large numbers of immunocompromised patients on steroid therapy or with uncontrolled diabetes.
Pathogens in Indian CAP — What's Different
Unlike Western populations where S. pneumoniae dominates, Indian studies (including data from PGIMER, AIIMS, and CMC Vellore) consistently show a higher proportion of gram-negative organisms — particularly Klebsiella pneumoniae, Acinetobacter spp., and Pseudomonas aeruginosa — especially in diabetic patients and those with prior antibiotic exposure. This has important implications: standard amoxicillin monotherapy is inadequate for moderate-to-severe Indian CAP; a combination of a beta-lactam plus a respiratory fluoroquinolone (levofloxacin or moxifloxacin) or a macrolide is preferred.
TB vs. CAP — A Critical Distinction
In India, pulmonary tuberculosis must always be considered in the differential for any patient presenting with cough, fever, and infiltrates — particularly if symptoms have been present for more than 2 weeks, if the patient has had prior TB or TB contact, or if there is significant weight loss. CURB-65 does not distinguish TB from bacterial CAP. A patient with smear-positive TB may score 0–1 and be sent home — only to deteriorate and remain infectious. Always obtain sputum AFB smear and GeneXpert if TB is suspected.
Empirical Antibiotic Therapy — India Guidance
| CURB-65 | Setting | Preferred Regimen (India) |
|---|---|---|
| 0–1 | Outpatient | Amoxicillin-clavulanate 625mg TDS or Azithromycin 500mg OD × 5 days |
| 2 | Ward admission | IV Ampicillin-sulbactam + Azithromycin or Levofloxacin 750mg OD |
| 3–4 | Ward / HDU | IV Piperacillin-tazobactam + Levofloxacin; consider coverage for Klebsiella |
| 5 | ICU | Meropenem + Levofloxacin ± anti-MRSA (vancomycin) if risk factors present |
Antibiotic choices should be guided by local antibiogram data and modified based on culture results. These are empirical starting points only.
4What is the CURB-65 Score?
The CURB-65 score is a validated clinical prediction rule developed by Lim et al. in 2003 and endorsed by the British Thoracic Society (BTS) for stratifying the severity of community-acquired pneumonia (CAP). It uses five easily obtainable bedside and laboratory parameters to estimate 30-day all-cause mortality and guide the decision between outpatient, inpatient, and intensive care management.
Each parameter present is assigned 1 point. A total score ranges from 0 to 5. The score was derived from a cohort of over 1,000 patients across multiple UK hospitals and has since been externally validated in numerous international populations, including studies from India and Southeast Asia.
When to Use CURB-65
CURB-65 is best applied in emergency departments and inpatient wards where blood urea/BUN results are readily available. For primary care or community settings without lab access, the abbreviated CRB-65 (dropping the Urea parameter) is recommended as a practical alternative. Always interpret the score alongside clinical judgment, oxygenation status, radiology findings, and social circumstances.
Antibiotic Guidance by Severity
The IDSA/ATS guidelines recommend oral amoxicillin-clavulanate or respiratory fluoroquinolones for mild CAP (score 0–1), and IV beta-lactam plus a macrolide for moderate-severe CAP (score ≥2). For ICU-level patients, dual coverage with a beta-lactam plus either a macrolide or fluoroquinolone is standard. Atypical coverage (Legionella, Mycoplasma) should be considered in all hospitalized CAP patients.
Limitations to Be Aware Of
- Does not incorporate oxygenation or SpO₂ directly — a patient with SpO₂ <90% may score low but require admission
- Urea may be elevated due to dehydration, renal disease, or upper GI bleeding — false positivity is possible
- Does not assess bilateral or multilobar infiltrates, which independently worsen prognosis
- Not validated in aspiration pneumonia, healthcare-associated pneumonia, or immunocompromised hosts
- Functional status, social support, and comorbidities must supplement the numeric score
The CURB-65 metric serves as an objective tool to map pneumonia severity, yet low numerical values must never muffle active signs of severe hypoxaemia (SpO₂ < 90%) or uncompensated organ failure which dictate immediate admission.
Medical disclaimer: This calculator is for educational and clinical decision-support purposes only. It does not replace clinical judgment or specialist consultation. RxMedCalc is not liable for clinical decisions made solely on this tool.